U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal CancerBusiness Wire • 12/20/24
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with AnalystsBusiness Wire • 12/19/24
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?The Motley Fool • 12/19/24
Roam For the Holidays: Grindr Offers Free Access to Their Popular Travel FeatureBusiness Wire • 12/19/24
Pfizer Sets Up For A Wild Ride In 2025 Amid Looming Threats From Starboard, KennedyInvestors Business Daily • 12/18/24
Stock Of The Day: Is Pfizer About To Break Out? Expect A New Uptrend If Resistance BreaksBenzinga • 12/17/24
Pfizer Inc. (PFE) Full-Year 2025 Financial Guidance Conference Call (Transcript)Seeking Alpha • 12/17/24
Pfizer Stock Jumps On Mixed, But 'Marginally Encouraging,' 2025 OutlookInvestors Business Daily • 12/17/24
Pfizer Does Not Anticipate Material Changes To US Vaccine Policy From The Incoming Administration In 2025Benzinga • 12/17/24
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 GuidanceBusiness Wire • 12/17/24